English
Polski
Español
українська
Nintedanib and pirfenidone in patients with FVC <50%
What is your opinion on using nintedanib and pirfenidone in patients with forced vital capacity <50%? Are there any data available to support such treatment?
2017-03-02
What is your opinion on using nintedanib and pirfenidone in patients with forced vital capacity <50%? Are there any data available to support such treatment?
The use of noninvasive ventilation in asthma exacerbations is often discussed but rarely applied in daily practice. Which patients may benefit from this intervention?
There is a tendency to keep the duration of antibiotic treatment for community-acquired pneumonia as short as possible. Treatment of 5 days is safe and effective but is it associated with an increased risk of selection of resistant pathogens?
What should be the optimal pressures during long-term noninvasive ventilation in patients with chronic obstructive pulmonary disease?
In the European Union, the incidence of drug-resistant tuberculosis TB is low. However, the situation in Russia and former Soviet republics is very concerning. As these countries border Poland and are frequently travelled to and from, should we expect that the incidence of drug-resistant TB may increase in the regions of Poland adjacent to the border?
Do you think procalcitonin has a potential to replace C-reactive protein as the first-line diagnostic study in patients with suspected community-acquired pneumonia?
There are some data that noninvasive ventilation could be useful in long-term treatment of some patients with COPD. Apart from the information from arterial blood gas analysis, which data should we use to decide which stable hypercapnic patients with COPD will benefit most from NIV? Is there a subgroup of patients in whom this treatment should be routinely used?
Extrapulmonary TB constitutes <6% of all TB cases in Poland. This number is much below the EU average, which is about 22%. What might be the reasons for such a discrepancy, given that the prevalence of TB in Poland is about 18/100,000 and is significantly higher than in most EU countries? Could this mean that many cases of extrapulmonary TB are underdiagnosed in Poland?
A recently published paper discussed the use of CT as an initial study in patients presenting with suspected community-acquired pneumonia. The results were encouraging but not game-changing. When could a clinician consider CT in an outpatient presenting with symptoms of CAP?
What treatment would you recommend in a patient with idiopathic pulmonary fibrosis who cannot be treated with nintedanib or pirfenidone?
